Summary by Futu AI
Recursion Pharmaceuticals, Inc. CEO Christopher Gibson acquired 5,000 shares of the company's Class A Common Stock on 08/23/2024. The transaction was executed at a price of $2.48 per share, indicating a total investment of $12,400. Following this purchase, Gibson's direct holdings in the company increased to 737,656 shares. The transaction, which is currently in progress, was reported as an exercise or conversion of derivative security.